GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

In addition, data from the Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus (CP) does not support further development. A global biopharmaceutical company on a mission to Solve On.

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause ...

Incyte stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...

Are you being struck by the sudden and intense need to itch your legs, arms or torso, particularly at night? Then you might be falling victim to the pesky 'winter itch', a common type of skin ...

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...